LewisRSilvermanMD

Hematologic Oncology

Associate Professor of Medicine, Mount Sinai School of Medicine

Overview of Dr. Silverman

Dr. Lewis Silverman is an oncologist in New York, NY and is affiliated with The Mount Sinai Hospital. He received his medical degree from Universite Libre de Bruxelles Faculty of Medicine and has been in practice 39 years. Dr. Silverman accepts several types of health insurance, listed below. He is one of 190 doctors at The Mount Sinai Hospital who specialize in Oncology. He has more than 90 publications and over 500 citings.

Office
10 E 102nd St
New York, NY 10029
Book by Phone+1(415) 944-3872

Fax+1 212-731-5210

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1983 - 1984
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1982 - 1983
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1980 - 1981
New York Medical College (Metropolitan)Residency, Internal Medicine, 1978 - 1980
Universite Libre de Bruxelles Faculty of MedicineClass of 1978

Certifications & Licensure

NY State Medical License 1979 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors: New York Metro Area Castle Connolly, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia Start of enrollment: 1999 Apr 01
Active, not recruiting
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma Start of enrollment: 1984 Jun 01
Active, not recruiting
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia Start of enrollment: 2006 Nov 22
Active, not recruiting
Phase 1, Phase 2
Research Tissue Bank Start of enrollment: 2007 Sep 01
Completed
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) Start of enrollment: 2008 Oct 01
Completed
Phase 1
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 1996 May 01
Active, not recruiting
Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs Start of enrollment: 2013 Jul 01
Completed
Phase 2
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Start of enrollment: 2013 Aug 01
Completed
Phase 3
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Start of enrollment: 2015 Dec 02
Terminated
Phase 3
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) Start of enrollment: 2022 Sep 28
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes Start of enrollment: 2024 Jan 11
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1399 citations
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson, Alice B. Kornblith, Jimmie C. Holland
Journal of Clinical Oncology. 2002-05-15
50 citations
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome
Lewis R. Silverman, Ghulam J. Mufti
Nature Clinical Practice. Oncology. 2005-12-01
38 citations
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Michael Heuser, Neil Palmisiano, Ioannis Mantzaris, Alice S. Mims, Courtney D. DiNardo
Leukemia. 2020-11-01

Abstracts/Posters

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...
Lewis R. Silverman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin
Lewis R. Silverman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/_-Catenin Signaling and Downstream Hematopoi...
Lewis R. Silverman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...
Lewis R. Silverman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)
Lewis R. Silverman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to Be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York CityJanuary 31st, 2019

Grant Support

MPD Clinical ConsortiumNational Cancer Institute2011
Clinical Trial: On 01910na In Patients With Refractory Lukemia Or MyelodysplastNational Center For Research Resources2009
MPD Clinical ConsortiumNational Cancer Institute2007–2009
MPD Clinical ConsortiumNational Cancer Institute2006
Cancer And Leukemia Group B--Mount SinaiNational Cancer Institute2001–2002

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment